A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia
A phase 3 trial of Glasdegib, CPX-351, Azacitidine and Cytarabine in Leukaemia, run by Pfizer, completed.
Overview
A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia is a phase 3 interventional study registered as NCT03416179 by Pfizer, with 730 participants recorded, started 2018-04-20 and reaching its primary completion in 2020-06-05. Interventions recorded: glasdegib, daunorubicin + cytarabine, azacitidine, Placebo, Placebo, glasdegib, cytarabine, HSCT. Conditions recorded: Leukemia, Myeloid, Acute.
Linked to the drug Glasdegib because the registry names it among its interventions and Leukaemia among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialContinuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML
Shares Glasdegib, Leukaemia (all types), Azacitidine, Pfizer (incl. Seagen) and the tag pipeline.
- TrialGemtuzumab Ozogamicin in Induction and Glasdegib in Postremission Therapy in Patients With AML (Acute Myeloid Leukemia)
Shares Glasdegib and the tag pipeline.
- TrialStudy to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients With Acute Myeloid Leukemia Not Eligible for Standard Chemotherapy
Shares Leukaemia (all types), Azacitidine and the tag pipeline.
- TrialA Safety and Efficacy Study of Eltrombopag in Subjects With AML
Shares Cytarabine, Leukaemia (all types) and the tag pipeline.
- TrialPevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Shares Leukaemia (all types), Azacitidine and the tag pipeline.
- TrialGalinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2
Shares Cytarabine, Azacitidine and the tag pipeline.
- TrialStudy of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients
Shares Leukaemia (all types), Azacitidine and the tag pipeline.
- TrialStudy of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated
Shares Cytarabine, Azacitidine and the tag pipeline.